1. Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2011 report is available on www.goldcopd.com
2. Panning CA, DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183–9.
3. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med 2010; 16: 97–105.
4. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55.
5. Vincken W, van Noord JA, Greefhorst APM et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotopium. Eur Respir J 2002; 19: 209–16.
6. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 1: 217–24.
7. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404.
8. Celli B, Wallack RZ, Wang S et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–8.
9. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–48.
10. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.
11. Decramer M, Celli B, Kesten S et al. for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–8.
12. Troosters T, Celli B, Lystig T et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010; 36: 65–73.
13. Morice AH, Celli B, Kesten S et al. COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010; 104: 1659–67.
14. van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
15. Baloira Villar A, Vilariño Pombo C. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2005; 41: 130–4.
16. Vogelmeier C, Kardos P, Harari S et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008; 102: 1511–20.
17. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134: 255–62.
18. Mahler DA, D’Urzo A, Bateman ED et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67: 781–8.
19. Aalbers R, Maleki-Yazdi MR, Hamilton A et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the RespimatR inhaler in patients with COPD. Proceedings of ERS Annual Congress, Vienna, 2012: p. 2882.
20. van Noord JA, Smeets JJ, Drenth BM et al. 24-hour bronchodilation following a single dose of the novel b(2)-agonist olodaterol in COPD. Pulm Pharmacol Ther 2011; 24: 666–72.
21. Bouyssou T, Casarosa P, Naline E et al. Pharmacological Characterization of Olodaterol, a Novel Inhaled b2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models. JPET 2010; 334: 53–62.
22. Maltais F, Beck E, Webster D et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur Respir J 2010; 36 (Suppl. 54): 5557.
23. Short PM, Williamson PA, Elder DHJ et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting b-agonist therapy in COPD. Chest 2012; 141: 81–6.
24. Criner GJ, Scharf SM, Falk JA. National Emphysema Treatment Trial Research Group et al. Effect of lung volume reduction surgery on resting pulmonary hemodynamics in severe emphysema. Am J Respir Crit Care Med 2007; 176: 253–60.
25. Jörgensen K, Houltz E, Westfelt U et al. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest 2003; 124: 1863–70.
26. Donaldson GC, Wedzicha JA. COPD exacerbations: epidemiology. Thorax 2006; 61: 164–8.
27. Briggs DD Jr, Covelli H, Lapidus R et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005; 18: 397–404.
28. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093–103.
29. Koegler H, Rabe KF, Beeh KM et al. Association of b2-adrenoreceptor genotypes with prevention of COPD exacerbations by tiotropium or salmeterol in the POET-COPDR trial. Proceedings of ERS Annual Congress, Vienna, 2012: p. 2879.
30. Turki J, Pak J, Green SA et al. Genetic polymorphisms of the b2-adrenergic receptor in noctural and non-noctural asthma. Evidence t hat Gly 16 correlated with the noctural phenotype. J Clin Invest 1995; 95: 1635–41.
31. Liggett SB. Polymorphisms of the b2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997; 156: 156–62.
32. Reihsaus E, Innis M, Liggett SB. Mutations in the gene encoding for the b2-adrenoreceptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8: 334–9.
33. Ulbrecht M, Hergeth MK, Wist M. Association of b2-adrenoreceptor variants with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 161: 469–74.
34. Kim SH, Oh HB, Oh SI. Association of b2-adrenoreceptor polymorphism with noctural cough among atopic subjects but not with atopy and nonspecific BHR. J Allergy Clin Immunol. 2002; 109: 630–5.
35. Peters SP, Kunselman SJ, Icitovic N et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715–26.
36. Kerstjens HAM, Engel M, Dahl R et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198–207.

С.Н.Авдеев

ФГБУ НИИ пульмонологии ФМБА России